Currently an estimated 17 million nuclear medicine procedures are performed each year in the US and constantly evolving, as new radiopharmaceuticals and imaging techniques are introduced for better diagnosis and treatment of human diseases. In keeping up with new developments, the Seventh Edition of Fundamentals of Nuclear Pharmacy chronicles the advancements in radiopharmaceuticals and their use in clinical applications. It discusses basic concepts such as the atom, radioactive decay, instrumentation and production of radionuclides, and explores the design, labeling, characteristics and quality control of radiopharmaceuticals. Radiation regulations and diagnostic and therapeutic applications of radiopharmaceuticals are detailed. Thoroughly updated, the Seventh Edition includes new topics such as alternative productions of 99Mo; production of 64Cu, 86Y, 89Zr, 177Lu, 223Ra; synthesis and clinical uses of new radiopharmaceuticals such as DaTscan, Xofigo, Amyvid, Neuraceq, Vizamyl, Axumin and 68Ga-DOTATATE; dosimetry of new radiopharmaceuticals; theranostic agents and translational medicine. It features numerous examples, diagrams, and images to further clarify the information and offers end- of-chapter questions to help readers assess their comprehension of the material. Recognized as a classic text on nuclear chemistry and pharmacy and acclaimed for its concise and easy-to-understand presentation, Fundamentals of Nuclear Pharmacy is an authoritative resource for nuclear medicine physicians, residents, students, and technologists.

Completed revised and updated, Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine, 4th Edition is the radiopharmaceutical bible for nuclear pharmacists, nuclear medicine physicians, and nuclear medicine technologists. Useful in educational programs across these disciplines, it also serves as a key reference in preparation for specialty board examination in nuclear medicine and nuclear pharmacy. The book contains essential information required by state and federal radiation licensing organization for specialty practitioners preparing to become authorized nuclear pharmacists or authorized nuclear medicine physicians. Key Features: - All chapters are entirely reorganized and revised to reflect the latest developments in the field - Chapters new to the fourth edition cover of range of topics including Adverse Reactions to Radiopharmaceuticals, Pregnancy and Pediatrics, Localization Mechanisms of Radiopharmaceuticals, Non-Radioactive Pharmaceuticals, PET Manufacturing, and Radiopharmaceutical Distribution. - Over 500 figures and 200 tables--many in full-color--underscore key concepts

This innovative textbook offers a comprehensive introduction to nuclear medicine with focus on the application of basic information. Nuclear Pharmacy will appeal to those wanting an accessible introduction to the topic, as well as those who would want to use it as a reference. Essential information on nuclear pharmacy is discussed, covering* introduction to basic nuclear physics * radioactive decay* radiopharmaceuticals* practice of nuclear pharmacy* methods for acquiring and using radiopharmaceuticals in the nuclear medicine department. Nuclear Pharmacy will be an invaluable resource for any pharmacy student, pharmacist, physician, nuclear pharmacy technician, radiology resident, and anyone seeking to explore and understand this fascinating field. Blaine Templar Smith is Chair at the Department of Pharmaceutical Sciences, Saint Joseph College School of Pharmacy,USA.

Nearly 20 million nuclear medicine procedures are carried out each year in the United States alone to diagnose and treat cancers, cardiovascular disease, and certain neurological disorders. Many of the advancements in nuclear medicine have been the result of research investments made during the past 50 years where these procedures are now a routine part of clinical care. Although nuclear medicine plays an important role in biomedical research and disease management, its promise is only beginning to be realized. Advancing Nuclear Medicine Through Innovation highlights the exciting emerging opportunities in nuclear medicine, which include assessing the efficacy of new drugs in development, individualizing treatment to the patient, and understanding the biology of human diseases. Health care and pharmaceutical professionals will be most interested in this book's examination of the challenges the field faces and its recommendations for ways to reduce these impediments.

The decay product of the medical isotope molybdenum-99 (Mo-99), technetium-99m (Tc-99m), and associated medical isotopes iodine-131 (I-131) and xenon-133 (Xe-133) are used worldwide for medical diagnostic imaging or therapy. The United States consumes about half of the world's supply of Mo-99, but there has been no domestic (i.e., U.S.-based) production of this isotope since the late 1980s. The United States imports Mo-99 for domestic use from Australia, Canada, Europe, and South Africa. Mo-99 and Tc-99m cannot be stockpiled for use because of their short half-lives. Consequently, they must be routinely produced and delivered to medical imaging centers. Almost all Mo-99 for medical use is produced by irradiating highly enriched uranium (HEU) targets in research reactors, several of which are over 50 years old and are approaching the end of their operating lives. Unanticipated and extended shutdowns of some of these old reactors have resulted in severe Mo-99 supply shortages in the United States and other countries. Some of these shortages have disrupted the delivery of medical care. Molybdenum-99 for Medical Imaging examines the production and utilization of Mo-99 and associated medical isotopes, and provides recommendations for medical use.

This textbook brings together information on advances in radiopharmacy, providing a basic guide to the art and science of the field. This edition has been completely revised and updated to reflect developments in the science and practice of radiopharmacy that have taken place over the last ten years. It is divided into 6 sections: physics applied to radiopharmacy, medicinal radio-elements, radiopharmacology and radiopharmacokinetics, radiopharmaceutics, formulation, preparation and quality assurance, radiopharmacy practice, new techniques for design and testing of radiopharmaceuticals.

Participants of the July 17-18, 2017, symposium titled Opportunities and Approaches for Supplying Molybdenum-99 and Associated Medical Isotopes to Global Markets examined current trends in molybdenum-99 production, prospects for new global supplies, and technical, economic, regulatory, and other considerations for supplying molybdenum-99 to global markets. This publication summarizes the presentations and discussions from the symposium.